Findings

What do systematic reviews say?

335 questions · 340 findings · 46 reviews · Pain, Palliative and Supportive Care

Sort:Best matchNewest Highest certainty Download CSV

No studies found 66 · 19.4%GRADE not reported 16 · 4.7%Very low 102 · 30%Low 68 · 20%Moderate 59 · 17.4%High 29 · 8.5%

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

rolapitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

netupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosnetupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Moderate

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosnetupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

rolapitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

netupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
High

SSRIs or SNRIs vs placebo

Migraine frequency Number of attacks · patients for whom migraine preventive interventions are indicated

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 113 participants
Low

SSRIs or SNRIs vs amitriptyline

Migraine duration Hours · patients for whom migraine preventive interventions are indicated

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 104 participants
Low

SSRIs or SNRIs vs amitriptyline

Symptomatic/analgesic medication use for acute headache attacks · patients for whom migraine preventive interventions are indicated

The review found no eligible studies for this question.

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

SSRIs or SNRIs vs amitriptyline

Migraine index · patients for whom migraine preventive interventions are indicated

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 62 participants
Very low

SSRIs or SNRIs vs amitriptyline

Quality of life · patients for whom migraine preventive interventions are indicated

The review found no eligible studies for this question.

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

SSRIs or SNRIs vs amitriptyline

Participants who withdraw because of an adverse event or any other reason · patients for whom migraine preventive interventions are indicated

SSRIs or SNRIs showed no clear difference in withdrawn (for any reasons and due to adverse events) compared with amitriptyline (low certainty).

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
OR 0.39 [0.1, 1.5]
1 study · 64 participants
Low

SSRIs or SNRIs vs placebo

Migraine intensity Score · patients for whom migraine preventive interventions are indicated

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 113 participants
Low

SSRIs or SNRIs vs placebo

Migraine duration Hours · patients for whom migraine preventive interventions are indicated

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
GRADE not reported

SSRIs or SNRIs vs placebo

Symptomatic/analgesic medication use for acute headache attacks · patients for whom migraine preventive interventions are indicated

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 113 participants
Low

SSRIs or SNRIs vs placebo

Migraine index · patients for whom migraine preventive interventions are indicated

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 86 participants
Very low

SSRIs or SNRIs vs placebo

Quality of life · patients for whom migraine preventive interventions are indicated

The review found no eligible studies for this question.

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

SSRIs or SNRIs vs placebo

Number withdrawn due to adverse events · patients for whom migraine preventive interventions are indicated

It is very uncertain whether SSRIs or SNRIs changes withdrawn (due to adverse events) compared with placebo (very low certainty).

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
OR 1.95 [0.7, 5.44]
5 studies · 221 participants
Very low